Evidence map›Paper›PMID 39529479›Full record

ArticleeLife2024

Complete suspension culture of human induced pluripotent stem cells supplemented with suppressors of spontaneous differentiation.

Mami Matsuo-Takasaki, Sho Kambayashi, Yasuko Hemmi, Tamami Wakabayashi, Tomoya Shimizu, Yuri An, Hidenori Ito, Kazuhiro Takeuchi, Masato Ibuki, Terasu Kawashima and 12 more

Abstract read
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Mami Matsuo-TakasakiiPS Cell Advanced Characterization and Development Team, RIKEN BioResource Research Center, Ibaraki, Japan.
Sho KambayashiRegenerative Medicine and Cell Therapy Laboratories, KANEKA CORPORATION, Kobe, Japan.
Yasuko HemmiiPS Cell Advanced Characterization and Development Team, RIKEN BioResource Research Center, Ibaraki, Japan.
Tamami WakabayashiiPS Cell Advanced Characterization and Development Team, RIKEN BioResource Research Center, Ibaraki, Japan.
Tomoya ShimizuiPS Cell Advanced Characterization and Development Team, RIKEN BioResource Research Center, Ibaraki, Japan.
Yuri AniPS Cell Advanced Characterization and Development Team, RIKEN BioResource Research Center, Ibaraki, Japan.
Hidenori ItoiPS Cell Advanced Characterization and Development Team, RIKEN BioResource Research Center, Ibaraki, Japan.
Kazuhiro TakeuchiRegenerative Medicine and Cell Therapy Laboratories, KANEKA CORPORATION, Kobe, Japan.
Masato IbukiRegenerative Medicine and Cell Therapy Laboratories, KANEKA CORPORATION, Kobe, Japan.
Terasu KawashimaRegenerative Medicine and Cell Therapy Laboratories, KANEKA CORPORATION, Kobe, Japan.
Rio MasayasuRegenerative Medicine and Cell Therapy Laboratories, KANEKA CORPORATION, Kobe, Japan.
Manami SuzukiRegenerative Medicine and Cell Therapy Laboratories, KANEKA CORPORATION, Kobe, Japan.
Yoshikazu KawaiRegenerative Medicine and Cell Therapy Laboratories, KANEKA CORPORATION, Kobe, Japan.
Masafumi UmekageResearch and Development Center, CiRA Foundation, Kyoto, Japan.
Tomoaki M KatoResearch and Development Center, CiRA Foundation, Kyoto, Japan.
Michiya NoguchiCell Engineering Division, RIKEN BioResource Research Center, Ibaraki, Japan.
Koji NakadeGene Engineering Division, RIKEN BioResource Research Center, Ibaraki, Japan.
Yukio NakamuraCell Engineering Division, RIKEN BioResource Research Center, Ibaraki, Japan.
Tomoyuki NakaishiRegenerative Medicine and Cell Therapy Laboratories, KANEKA CORPORATION, Kobe, Japan.
Naoki NishishitaRegenerative Medicine and Cell Therapy Laboratories, KANEKA CORPORATION, Kobe, Japan.
Masayoshi TsukaharaResearch and Development Center, CiRA Foundation, Kyoto, Japan.
Yohei HayashiiPS Cell Advanced Characterization and Development Team, RIKEN BioResource Research Center, Ibaraki, Japan.ORCID https://orcid.org/0000-0001-5490-7052

Funding

Japan Agency for Medical Research and Development JP15bm0104001Japan Agency for Medical Research and Development JP23bm1423010
6 · The paper itself

Abstract

Human induced pluripotent stem cells (hiPSCs) are promising resources for producing various types of tissues in regenerative medicine; however, the improvement in a scalable culture system that can precisely control the cellular status of hiPSCs is needed. Utilizing suspension culture without microcarriers or special materials allows for massive production, automation, cost-effectiveness, and safety assurance in industrialized regenerative medicine. Here, we found that hiPSCs cultured in suspension conditions with continuous agitation without microcarriers or extracellular matrix components were more prone to spontaneous differentiation than those cultured in conventional adherent conditions. Adding PKCβ and Wnt signaling pathway inhibitors in the suspension conditions suppressed the spontaneous differentiation of hiPSCs into ectoderm and mesendoderm, respectively. In these conditions, we successfully completed the culture processes of hiPSCs, including the generation of hiPSCs from peripheral blood mononuclear cells with the expansion of bulk population and single-cell sorted clones, long-term culture with robust self-renewal characteristics, single-cell cloning, direct cryopreservation from suspension culture and their successful recovery, and efficient mass production of a clinical-grade hiPSC line. Our results demonstrate that precise control of the cellular status in suspension culture conditions paves the way for their stable and automated clinical application.

Indexed as

Cell Culture TechniquesCell DifferentiationInduced Pluripotent Stem CellsHumansLeukocytes, Mononuclearbioreactorhumaninduced pluripotent stem cellsprotein kinase Cregenerative medicinestem cellssuspension cultureWNT

Identifiers

PMID39529479
PMCPMC11556790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.